SOMAÍ, a prominent vertically integrated Multi-Country Operator (MCO) holding EU-GMP certification, has officially marked its entry into the Italian market. This significant expansion has been realized through a strategic partnership with Materia Medica Processing, a leading entity in Italy’s pharmaceutical cannabis sector.
Bringing Pharmaceutical-Grade Cannabinoid Medicines to Italy
The collaboration will introduce SOMAÍ’s range of pharmaceutical-grade cannabinoid medicines to an eagerly awaiting patient population and the broader healthcare professional community in Italy. This move addresses critical barriers that patients have historically faced in accessing high-quality, standardized treatments within the country. SOMAÍ’s mission to deliver premium cannabis-based therapeutics globally is further bolstered by this integration into the strategically important Italian market.
SOMAÍ’s expansion into Italy is part of a broader international growth strategy. The company already maintains a significant presence in Australia, the United Kingdom, and Germany. Looking ahead, SOMAÍ has ambitious plans to extend its reach into Ireland, Poland, and Switzerland, underscoring its commitment to global patient access.
Focus on Consistency, Accessibility, and Innovation
The partnership with Materia Medica Processing is set to introduce scientifically advanced cannabinoid therapies to Italy. A core focus of these therapies will be on ensuring consistency in product quality, enhancing accessibility for patients, and fostering innovation in patient care. This approach aims to elevate the standard of medical cannabis treatment available.
Michael Sassano, the CEO of SOMAÍ, commented on the significance of this latest venture. He highlighted the escalating demand for SOMAÍ’s specialized products and emphasized the strategic imperative of integrating into the Italian market. “The demand for our products continues to grow as more healthcare professionals and patients recognize the therapeutic potential of high-quality, standardized cannabinoid medicines,” Sassano stated. “Our entry into Italy is a crucial step in fulfilling our mission to make these advanced treatments accessible across key global markets.”
Advanced Formulations for Reliable Treatment
SOMAÍ distinguishes itself through its rigorous manufacturing processes, which include a meticulous multi-step extraction process. The company utilizes EU-GMP-certified formulations, ensuring that its products meet the highest international standards for pharmaceutical manufacturing. This commitment to quality is designed to support healthcare professionals and pharmacies, empowering them to provide reliable and effective medical cannabis treatments to their patients.
By combining its advanced production methodologies with a strategic market entry through Materia Medica Processing, SOMAÍ is positioned to make a substantial impact on the Italian medical cannabis landscape. The company’s dedication to scientific rigor and patient-centric care promises to bring a new level of quality and reliability to cannabinoid therapies in Italy, aligning with the growing global trend towards evidence-based medical cannabis solutions.
